Scholarlink

<p>Early frontline data presented at the 2025 ASH Annual Meeting suggest that T cell–redirecting strategies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), can induce rapid, high rates of minimal residual disease (MRD)-negative responses in newly diagnosed multiple myeloma (NDMM), including transplant-ineligible (TI) and high-risk populations. However, short follow-up, heterogeneous MRD methodologies, and infection risk—particularly with continuous bispecific exposure—underscore that these approaches remain investigational and should be advanced through randomized, MRD-guided fixed-duration trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Huixing Zhou,
  • Xiaoyun Jin,
  • Wenming Chen,
  • Hong-Hu Zhu,
  • Wen Gao

摘要

Early frontline data presented at the 2025 ASH Annual Meeting suggest that T cell–redirecting strategies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), can induce rapid, high rates of minimal residual disease (MRD)-negative responses in newly diagnosed multiple myeloma (NDMM), including transplant-ineligible (TI) and high-risk populations. However, short follow-up, heterogeneous MRD methodologies, and infection risk—particularly with continuous bispecific exposure—underscore that these approaches remain investigational and should be advanced through randomized, MRD-guided fixed-duration trials.